CGUB17077 / PRIME / Edward MessingResearch Question:
What are the good and bad effects of using the Tokyo-172 version of BCG with the currently
used BCG LIVE (TICE® BCG) version on people with bladder cancer receiving BCG in the
bladder and what are the good and bad effects of adding a BCG vaccination (given under
the skin) in addition to placing BCG in only the bladder?
Basic Study Information
Purpose:Location: Cancer Center - Urology
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin
(BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how
well it works compared with TICE BCG solution in treating patients with bladder cancer
that has not spread to muscle. BCG is a non-infectious bacteria that when instilled
into the bladder may stimulate the immune system to fight bladder cancer. Giving different
versions of BCG with vaccine therapy may prevent bladder cancer from returning.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03091660?term=S1602&rank=1
Study Reference #: CGUB17077
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amber Johnson
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search